Find Clinical Trials

Eligibility Criteria: Inclusion (must meet all three criteria): 1. Subjects with a prior adverse outcome in a prior pregnancy. Adverse outcome is defined as prior singleton preterm birth ( \< 37 weeks), SGA infant (defined as birthweight \< 10th percentile), preeclampsia with severe features, or stillbirth (fetal demise after 20 weeks gestation), as certified by an obstetrician 2. Patients with maternal vascular malperfusion on pathology from pregnancy with prior adverse pregnancy outcome, as certified by a perinatal placental pathologist 3. Current singleton pregnancy at \<16 6/7 weeks gestational age. Exclusion Criteria: 1. Anticoagulation planned for current pregnancy (including warfarin, enoxaparin, heparin) 2. Known major fetal anomaly 3. Contraindication to enoxaparin: Specifically active major bleeding, known thrombocytopenia (platelets \<100), hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol 4. Chronic kidney disease with eGFR\< 60 5. Known chronic liver disease with baseline AST/ALT \> 3 x upper limit of normal 6. Subjects with mechanical prosthetic heart valves

Inclusion Criteria: * Age greater than or equal to 18 years * Single pregnancy * No previous pregnancies lasting more than 12 weeks * Participant willing and able to give informed consent for participation in the study Exclusion Criteria: * Intermediate-high risk of genetic abnormalities and/or need to perform invasive tests (amniocentesis, villocentesis) * History of solid organ or hematopoietic stem cell transplantation * Chronic renal failure (eGFR≤45ml/min/1.73m2) * Chronic treatment with antihypertensive drugs and/or xanthine oxidase (XO) inhibitors

Inclusion Criteria: * Individuals age 40 and older. * Living independently in an affordable housing development. * Have a cell phone that can receive and send text messages (SMS). Exclusion Criteria: * Self-reported terminal illness with life expectancy less than 1 year. * Inability to provide informed consent due to dementia or other reasons.

Inclusion Criteria: * Age ≥ 18 years * Female assigned at birth * Biopsy proven breast cancer (stage I-IV) * Treatment with therapy anthracycline-based chemo (with or without HER2-targeted therapy), with \>/= 2 cycles of anthracycline chemotherapy planned. * SBP ≥130 mm Hg * Willing and able to comply with the requirements of the protocol. * Participant must have and be willing to use their bluetooth enabled wifi or cellular mobile device * (For participants in the CPET cohort): Able to complete an acceptable baseline CPET, in the absence of high-risk ECG findings or other inappropriate response to exercise as determined by the PI, as defined by any of the following criteria: * Achieving a plateau oxygen consumption, concurrent with an increase in power output; * A respiratory exchange ratio ≥ 1.10; * Attainment of maximal predicted heart rate, as defined by a peak heart rate within 10bpm of the age predicted maximal heart rate (220 - Age\[years\]); * Volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale. Exclusion Criteria: * eGFR \< 30 ml/min/1.73m2 (based upon Cockcroft-Gault, etc.) * Individuals with arm circumference too large to allow accurate BP measurement with available BP devices * Inability to accurately measure blood pressure in at least one arm (e.g., bilateral upper extremity lymphedema) * Cardiac comorbidity, including any of the following: * Acute coronary syndrome within 3 months prior to randomization. * Symptomatic heart failure (NYHA class III/IV) within past 6 months * History of stroke * Cardiac transplantation * Other medical disorder or condition that in the opinion of the investigator would impair the subject's ability to participate or adhere to study interventions * (For participants in the CPET cohort): Subjects must not have any of the following absolute contraindications to cardiopulmonary exercise testing: * Acute myocardial infarction (within 30 days of any planned study procedures), * Unstable angina * Uncontrolled arrhythmias causing symptoms or hemodynamic compromise, * Symptomatic severe aortic stenosis * Recurrent syncope * Active endocarditis * Acute myocarditis or pericarditis * Acute pulmonary embolus or pulmonary infarction (within 3 months of any planned study procedures) * Thrombosis of lower extremities (within 3 months of any planned study procedures) * Suspected dissecting aneurysm * Uncontrolled asthma * Pulmonary edema * Room air desaturation at rest ≤85% * Respiratory failure * Acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis) * Mental impairment leading to inability to cooperate.

Inclusion Criteria: Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers: * Consent form read, understood, approved and signed before any study procedure * Membership of a social security scheme or beneficiary of such a scheme * Patient aged over 18 Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled exacerbation: \- Diagnosis of severe asthma confirmed by a respirologist at an expert centre Case asthma controlled: \- Asthma control confirmed by a lung specialist from an expert centre Case uncontrolled asthma excluding exacerbation: \- Uncontrolled asthma confirmed by a lung specialist from an expert centre Case uncontrolled asthma with exacerbation: \- Current exacerbation Exclusion Criteria: Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers: * Person subject to a legal protection measure * Vulnerable population: minors, persons under guardianship or trusteeship or persons deprived of their rights to liberty by court order. * women with a known pregnancy * Inability or refusal to comply with research requirements * Active or weaned smoker \> 15 PA * Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or opioids in the 10 days prior to inclusion Case patient with asthma: \- Coexistence of a chronic inflammatory disease other than asthma Case healthy volunteers: \- Coexistence of an inflammatory pathology Exclusion criteria: Cases asthma: Pregnancy during follow-up Cases healthy volunteers: Total IgE level greater than 100 kU/L (measured on the study sample)

Inclusion Criteria: 1. Children between the ages of 2 and 12 years old 2. Children must reside in one of the identified catchment areas 3. Children must meet the screening criteria as having not well controlled or poorly controlled asthma Exclusion Criteria: 1\. Children with complex medical conditions

Inclusion Criteria: * scoring in the clinical range on a self-report measure of depression severity (the PHQ-9) meeting diagnostic criteria for depression based on a diagnosis on Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders (DIAMOND) meeting diagnostic criteria for Bipolar I or II Disorder DIAMOND) participants will require a working knowledge of written and spoken Icelandic, sufficient to make use of therapy and complete research assessments without the need for a translator. Exclusion Criteria: * current/past learning disability, organic brain change, substance dependence (drugs and alcohol) that would compromise the ability to use therapy * current marked risk to self (i.e., self-harm or suicide) that we deem could not be appropriately managed in the Bipolar outpatient clinic at Landspitali. * currently lacking the capacity to give informed consent * currently receiving other psychosocial therapy for depression or bipolar disorder * presence of another area of difficulty that the therapist and client believe should be the primary focus of intervention (for example, Post-Traumatic Stress Disorder, psychosis)

Inclusion Criteria: written signed informed consent * Patient is able to understand and comply with the protocol for the duration of the clinical trial including undergoing treatment and scheduled visits and examinations * Patients with progressing metastatic CRC who were previously treated with FOLFOX, FOLFIRI, FOLFOXIRI, TAS-102, or regorafenib, if applicable in combination with anti-VEGFR monoclonal antibody (mAb) and anti-EGFR mAb (the latter, if RAS-wild-type and left sided tumors). In case of MSI-high/dMMR tumors, patients should have received checkpoint inhibitor therapy and at least two further lines of therapy of that stated above. In case of patients BRAF V600E mutation patients should have received: Cetuximab in combination with encorafenib in second- or third-line treatment. * At least one measurable lesion that can be accurately assessed at baseline by CT or MRI and is suitable for repeated assessment per RECIST 1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2 * Patient aged ≥ 18, no upper limit * Female patients of child bearing potential (FCBP) and male patients with partners of child bearing potential, who are sexually active, must agree to the use of two effective forms (at least one highly effective method) of contraception. This should be started from the signing of the informed consent and continue throughout period of taking study treatment and for 2 months after last dose of study drug. * For FCBP two negative pregnancy test (sensitivity of at least 25 mU/ml) prior to first application of CC-3 * All subjects must agree to refrain from donating blood while on study drug and for 2 months after last dose of CC-3. * Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 14 days prior to study treatment: * Hemoglobin ≥ 9 g/dl (Transfusion of packed red blood cells prior to enrolment allowed) * Neutrophil count ≥ 1,500/mm3 * Platelet count ≥ 75,000/µl * Serum creatinine ≤ 1.5mg/dl or creatinine clearance ≥ 60ml/min * hepatic function of patients without current hepatic metastasis: * Bilirubin ≤ 1.5x upper limit of normal (ULN), in case of known Gilbert syndrome higher values are allowed if due to increase of indirect bilirubin * ALT and AST ≤ 2.5 x ULN * hepatic function of patients with current hepatic metastasis: * Bilirubin ≤ 2.5 x upper limit of normal (ULN) * ALT and AST ≤ 5. x ULN Exclusion Criteria: * Other malignancy requiring treatment within the last year except: adequately treated non-melanoma skin cancer and low-grade non-muscle invasive papillary bladder cancer. * Concurrent or previous treatment within 30 days in another interventional clinical trial with an investigational anticancer therapy * Persistent toxicity (≥ Grade 2 according to Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0) caused by previous cancer therapy, excluding alopecia and neurotoxicity * Clinical signs of active infection (\> grade 2 according to CTCAE version 5.0) * Known cerebral/meningeal manifestation of CRC * History of HIV infection * Viral active or chronic hepatitis (HBV or HCV) * Ongoing autoimmune disease * History of relevant CNS pathology or current relevant CNS pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder) * Therapeutic anticoagulation therapy * Major surgery within 4 weeks of starting study treatment. Patients must have recovered from any effects of major surgery. * Patients receiving any systemic chemotherapy, mAb or radiotherapy within 2 (for mAb 4) weeks prior to study treatment or a longer period depending on the defined characteristics of the agents used * Heart failure NYHA III/IV * Severe obstructive or restrictive ventilation disorder * Known intolerance to CC-3 or other immunoglobulin drug products as well as hypersensitivity to any of the excipients present in CC-3 * Live and live-attenuated vaccination 30 days prior to treatment * Pregnant or breast-feeding women * Current ileus with severely altered GI function

Inclusion Criteria: 1. Age ≥18 years old, male or female; 2. Advanced, metastatic or recurrent malignant tumors diagnosed by histology or pathology, mainly colorectal cancer, esophageal cancer, gastric cancer, and pancreatic cancer; 3. After receiving at least second-line standard treatment failure (disease progression or intolerance, such as surgery, chemotherapy, radiotherapy, etc.) or lack of effective treatment methods; 4. Immunohistochemical staining of tumor samples within 3 months confirmed that the tumor was CEA positive (clear membrane staining, positive rate ≥ 10%); , the positive rate ≥ 10%), the serum CEA of the patient is required to exceed 10ug/L. 5. At least one assessable lesion according to RECIST 1.1 criteria; 6. ECOG score 0-2 points; 7. No serious mental disorder; 8. Unless otherwise specified, the function of the vital organs of the subject shall meet the following conditions: 1. Blood routine: white blood cells\>3.0×10\^9/L, neutrophils\>0.8×10\^9/L, lymphocytes cells\>0.5×10\^9/L, platelets\>75×10\^9/L, hemoglobin\>80g/L; 2. Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram; 3. Renal function: serum creatinine≤2.0×ULN; 4. Liver function: ALT and AST ≤3.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤5.0×ULN); 5. Total bilirubin≤3.0×ULN; 6. Oxygen saturation ≥95% in non-oxygen state. 9. Have apheresis or venous blood collection standards, and have no other contraindications for cell collection; 10. Subjects agree to use reliable and effective contraceptive methods for contraception within 1 year after signing the informed consent form to receiving CAR-T cell infusion (excluding rhythm contraception); 11. The patients themselves or their guardians agree to participate in this clinical trial and sign the ICF, indicating that they understand the purpose and procedures of this clinical trial and are willing to participate in the research. Exclusion Criteria: 1. Those who have central nervous system metastasis or meningeal metastasis at the time of screening are judged by the investigator to be unsuitable for inclusion; 2. Participated in other clinical studies within 1 month before screening; 3. vaccinated with live attenuated vaccine within 4 weeks before screening; 4. Received the following anti-tumor treatments before screening: Received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter); 5. Active infection or uncontrollable infection requiring systemic treatment; 6. Patients with intestinal obstruction, active gastrointestinal bleeding, or a history of gastrointestinal bleeding within 3 months; 7. Except for alopecia or peripheral neuropathy, the toxicity of previous anti-tumor therapy has not improved to the baseline level or ≤ grade 1; 8. Suffering from any of the following heart diseases: 1. New York Heart Association (NYHA) stage III or IV congestive heart failure; 2. Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months before enrollment; 3. Clinically significant ventricular arrhythmia, or a history of unexplained syncope (except those caused by vasovagal or dehydration); 4. History of severe non-ischemic cardiomyopathy; 9. Patients with active autoimmune disease, or other patients requiring long-term immunosuppressive therapy; 10. Suffering from other uncured malignant tumors in the past 3 years or at the same time, except cervical carcinoma in situ and basal cell carcinoma of the skin; 11. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer test is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive; 12. Women who are pregnant or breastfeeding; 13. Other investigators deem it unsuitable to participate in the research.

Inclusion Criteria: 1. 18 to 80 years of age 2. No tobacco/nicotine use within preceding 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches) 3. Systolic blood pressure \<140 mmHg; diastolic blood pressure \<90 mmHg (obtained at the Screening and Familiarization Visit) 4. Normal 12-lead ECG (obtained at the Screening and Familiarization Visit and reviewed by a board-certified physician) 5. Normal clinical results from a medical exam reviewed by a board-certified physician (e.g., General Health Questionnaire obtained at the Screening and Familiarization Visit) 6. Body mass index (BMI) \<35 unless athletic/muscular build; calculation = body weight (kg)/height (m2); 7. Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions unless post-menopausal Exclusion Criteria: 1. Not meeting the defined age criteria 2. Body mass index (BMI) \>35 unless athletic/muscular build; calculation = body weight (kg)/height (m2) 3. Any tobacco/nicotine use within the last 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches) 4. Positive pregnancy test 5. Females with an erratic/irregular menstrual cycle 6. Females who are breastfeeding 7. Women who are prescribed a continually releasing hormonal contraceptive (e.g. NuvaRingTM or other hormone releasing vaginal rings, Depo Provera shot, or birth control implants such as Nexplanon) 8. Subjects who weigh less than 80 lbs. 9. Use of prescription drugs, non-prescription drugs, dietary supplements or herbal medicines known to alter vascular function unless cleared prior to the study 10. Use of beta blockers 11. Daily use of bronchodilators 12. Use of anti-coagulant therapy 13. Implanted medical devices (e.g. cardiac pacemaker) 14. Current or past history of hyperthyroidism, or other thyroid hormone-related disease 15. Current use of hormone replacement therapy (e.g., estrogen, testosterone) 16. HbA1c \>5.6 17. Resting systolic blood pressure of \<100 mmHg; \>140mmHg or diastolic blood pressure \>90mmHg 18. Abnormal 12-lead ECG or uncontrolled heart rhythm issues causing symptoms, or an unstable blood pressure 19. History of cerebrovascular abnormalities (e.g., prior stroke, transient ischemic attacks, epilepsy) 20. Known history of atherosclerosis of the carotid arteries (i.e., plaque formation) 21. History of concussion and or other loss of consciousness within the preceding 30 days 22. Autonomic dysfunction (e.g., Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus arrhythmia, idiopathic orthostatic hypotension, fainting disorder) 23. Respiratory illnesses (e.g., chronic asthma (including exercise-induced asthma), Chronic Obstructive Pulmonary Disease, Reactive Airway Disease) 24. Any prior history of anaphylaxis, not just prior reactions to the materials used in this study 25. Severe phobia of needles 26. Latex allergy aa) Known allergies or sensitivities to substances used in the study (e.g., Lidocaine HCL, sodium nitroprusside, acetylcholine, phentolamine, L-NAME, TUDCA, or related drugs) bb) Donated blood within the last 60 days cc) History or family history of abnormal blood clotting, clots in deep veins in the legs or pelvis, or blood clots to the lungs dd) History of alcohol or drug abuse which inhibits the subject's ability to complete this study ee) Individuals who have had mastectomies ff) History of methemoglobinemia gg) Current diagnosis of anemia hh) Current Fever (oral temp \>99.5 °F/ 37.5 °C) ii) Current use of PDE3 inhibitors (e.g., Viagra) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat), or unwillingness to withhold medication for 2 weeks prior to laboratory testing jj) Current diagnosis of cancer kk) Cardiac surgery or cardiac events (e.g., coronary artery bypass graft surgery, myocardial infarction, heart failure) ll) Diagnosis of neurological disease or cognitive dysfunction

Inclusion Criteria: 1.18 to 75 years old (at the time of signing the informed consent form), regardless of gender. 2\. Subject type and disease characteristics. Histologically confirmed HER2 positive EBC subjects: 1. evaluated as HER2 positive in local laboratories according to ASCOCAP guidelines. 2. Single and multifocal tumors (greater than 1 tumor area limited to the same quadrant as the primary tumor) must be sampled from 1 lesion and laboratory confirmed as HER2 positive. 3. Multicenter tumors (multiple tumors involving more than one breast quadrant) must sample one lesion from each affected quadrant and be confirmed as HER2 positive by the central laboratory. 4. According to ASCOCAP guidelines, tumors are either HR positive or HR negative (ER and PgR negative). 5. Clinical staging at visit (based on breast X-ray or breast MRI evaluation): Stage II-IIIC determined by the AJCC staging system, 8th edition. (f) Lymph node involvement is determined by fine needle aspiration or coarse needle aspiration biopsy (if applicable). 3\. When randomized, ECOG physical fitness status is 0 or 1 point. Exclusion Criteria: 1. Previous history of invasive breast cancer. 2. Stage IV breast cancer according to AJCC staging system version 8. 3. Within 3 years, there is any primary malignant tumor, except for fully resected non-melanoma skin cancer or cured in situ disease. 4. DCIS medical history, except for the subjects who only received Mastectomy 5. According to the judgment of the researchers, there is evidence of any diseases (such as severe or uncontrolled systemic diseases, including persistent or active infections, uncontrolled hypertension, kidney transplantation and active bleeding diseases, and severe chronic gastrointestinal diseases related to diarrhea) that the researchers consider to be unfavorable for the participants to participate in the study or may affect adherence to the protocol. 6. Uncontrolled infection requiring intravenous administration of antibiotics, Antiviral drug or antifungal drugs.

An individual must meet the following criteria to be considered eligible to participate in the study: Inclusion Criteria: All subjects: * Female or male sex assigned at birth; * Age 18-65; * Normal or corrected to normal vision/hearing, as protocol elements may not be valid otherwise; * Fluent English speaker, capable of providing written informed consent MDD and AD-MDD subjects: * Current major depressive episode assessed by clinician with guidance from the MINI; * Minimum score of 55 on PROMIS Depression scale AD and AD-MDD subjects: * Current anxiety disorder (generalized anxiety disorder, panic disorder, agoraphobia and social phobia) assessed by clinician with guidance from the MINI; * Minimum score of 55 on PROMIS Anxiety Scale Exclusion Criteria: All subjects: * Has uncontrolled, clinically significant neurologic (including seizure disorders): cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease, or psychiatric disorder, or other abnormality, which may impact the ability of the subject to participate or potentially confound the study results; * Reported body mass index (BMI) \> 40; * History of moderate or severe traumatic brain injury, as assessed by a TBI questionnaire; * History of eating disorder or obsessive-compulsive disorder, schizophrenia, schizo-affective disorder, bipolar disorder or any sign of psychosis; * Current post-traumatic stress disorder (PTSD) diagnosis (although history of trauma is allowed); * Current use of medications with major effects on brain function or the fMRI hemodynamic response (e.g., methylphenidate, acetazolamide, excessive caffeine intake \> 1000 mg/day) following an initial list compiled by LIBR but also assessed on a case-by-case basis. Individuals who are currently on medication (antidepressants such as SSRIs, TCAs, SNRIs, and Bupropion) and who have not undergone dose or medication changes over the past 6 weeks will be allowed to participate; * Current benzodiazepine or opiate use; * Moderate to severe current substance use disorder, defined as 5 or more symptoms of the criteria for Substance Use Disorder according to DSM 5; * Drug or alcohol intoxication (based on positive UTOX or breathalyzer test at screening or study session) or reported alcohol/drug withdrawal, last cannabis use must be \>48 hours prior to study session; * Has a risk of suicide according to the Investigator's clinical judgement or per Columbia-Suicide Severity Rating Scale (C-SSRS) or equivalent PhenX instrument, the subject scores "yes" on items 4 or 5 in the Suicidal Ideation section with referent to a 30-day period prior to Screening/Baseline or the subject has had one or more suicidal attempts with reference to a 2-year period prior to Screening; * MRI contraindications; * Is pregnant or lactating or intending to become pregnant before, during, or within 12 weeks after participating in this study; or intending to donate ova during this time-period; * Any subject judged by the Investigator to be inappropriate for the study. MDD subjects: * Current (assessed by clinician with guidance from the MINI) anxiety disorder; * Score of \> 60 on PROMIS Anxiety Scale AD subjects: * Current or past recurrent major depressive episodes assessed by clinician with guidance from the MINI; * Score of \> 60 on PROMIS Depression scale

Inclusion Criteria: 1. Males or non-pregnant females 2. Ages 18-65 (inclusive) 3. Able/willing to give consent 4. Span the metabolic range between normal glycemia and pre-diabetes (fasting glucose of 100-125 mg/dL based on chart review of existing laboratory data) Exclusion Criteria: 1. Currently taking medications or intending to take medications for diabetes 2. Currently taking medications or intending to take medications that affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones 3. Personal history of intestinal malabsorption, bariatric surgery, celiac disease, gallbladder disease, or pancreatitis 4. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 5. Estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m2 per the Modification of Diet in Renal Disease equation 6. History of cirrhosis and/or aspartate aminotransferase or alanine aminotransferase more than 3x upper limit of normal 7. Dietary restrictions preventing consumption of a MMTT 8. Women who are pregnant, nursing, or at risk of becoming pregnant 9. Participation in other interventional studies during the current study

Inclusion Criteria: * Women who were identified as high risk on the retrospective study (dating from 2017-2025) using MIRAI will be recruited and consented for the prospective study * Women over 40 years of age identified as high risk according to traditional guidelines will also be potentially eligible for this study * Following consent and enrollment in the study, a participant will subsequently receive the following: 1. These patients will be invited to receive a supplemental MRI examination currently considered the most sensitive test for breast cancer detection. 2. Any positive diagnosis on MRI will be followed by biopsy to confirm 'truth" of diagnosis. * To be selected, a given record must include the following: 1. A report of a routine screening mammogram or diagnostic mammogram, and availability of the DICOM images from that report with the PACS system. 2. Reports of all follow up screening and diagnostic studies documented on PACS. 3. Some may have interventional procedures (as long as all of these are done at one of Umass sites) and documentation of these biopsy results in the hospitals EHR. Exclusion Criteria: * Under age 40. Women under 40 years are not routinely xrayed with a mammogram. * Xray breast cancer screening imaging study that has artifacts, corruption, or other image quality degradation. * Pregnant patients because they do not routinely receive screening mammogram * Adult male patients with breast cancer

Inclusion Criteria: \- overweight \[Body Mass Index (BMI) ≥ 27 kg/m2\] or obese (BMI ≥30 kg/m2) adult patients with diabetes mellitus and with a recent cardiovascular event and/or coronary revascularization in the previous three months Exclusion Criteria: * inability to walk independently and constantly; * acute joint or spine pathologies that make movement impossible; * the presence of dementia as approved by consultation of the patient's medical record and/or administration of the Montreal Cognitive Assessment (MOCA) test ≤ 15.5 (Nasreddine et al., 2005); * chemotherapy 6 months before surgery; * advanced renal failure; * acute cardiovascular event \< 3 months (unstable angina, AMI with FE \<40%, arrhythmias, valvular disease, intracerebral/subdural haemorrhage, uncontrolled AI); * home oxygen therapy and Non-Invasive Ventilation (NIV) \[excluding Continuous Positive Airway Pressure (CPAP)\].

Inclusion Criteria: 1. Patient with a characterized depressive episode defined according to DSM-5 (diagnostic and statistical manual of mental disorders) criteria; 2. Patient between the ages of 18 and 65 years; 3. Inpatient with an inadequate response to two prior well-conducted antidepressant treatments (Hamilton 17-item scale \[HAMD-17\] score at inclusion≥ 18) ; 4. Patient with written informed consent to participate in the study; 5. Patient enrolled in or receiving social security benefits. Exclusion Criteria: 1. Patient with endocrinopathy ; 2. Patient with a contraindication to neuroendocrine testing (hypersensitivity to the active substance or to one of the excipients); 3. Patient with a contraindication to rTMS: * cochlear implant, * cardiac pacemaker, * metal clips, stents or other electronic implants within one meter of the stimulation coil, * intracranial hypertension, * poorly balanced comitiality, * in the case of well-balanced comitiality, a neurological consultation with electroencephalogram (EEG) is planned before including the patient; 4. Patient previously treated with monoamine oxidase inhibitor (MAOI) antidepressant or lithium salts (within 6 months prior to inclusion); 5. Pregnant or lactating patient; 6. Patient under court protection or deprived of liberty; 7. Patient under guardianship/guardianship.

Inclusion Criteria: 1. Has the pathologically-confirmed diagnosis of locally recurrent or metastatic, hormone-receptor positive, HER2 negative Breast Cancer. 2. Age: 18 - 75 years old 3. Eastern Cooperative Oncology Group performance status (ECOG PS)=0\~1 4. Functions of liver and kidney is normal 5. Agreed to take contraceptive measures during treatment Exclusion Criteria: 1. Confirmed diagnosis of HER2 positive disease. 2. Central nervous system metastasis 3. Patients who received prior treatment with any CDK4/6 inhibitor. 4. Clinically significant cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure (New York heart association (NYHA) class \> 2), or ventricular arrhythmia which need medical intervention； 5. Researchers believe that is not suitable for the study

Inclusion Criteria: * Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab. * Those who voluntarily signed a written personal information agreement to participate in this clinical study. * Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion. Exclusion Criteria: * Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.) * Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1) * Those who are expected to need insulin prescription during the study period * Pregnant women, breast-feeding women

PATIENTS: Inclusion Criteria: * ≥ 65 years; * With multimorbidity (diabetes or hypertension plus one of the following: arthritis (osteoarthritis and rheumatoid arthritis), asthma, atrial fibrillation, Alzheimer's disease and related dementia (not severe), cancer, chronic obstructive pulmonary disease, depression, heart disease, heart failure, hyperlipidemia, osteoporosis, kidney disease and stroke. Patients with diabetes plus hypertension are eligible. * Have had two or more clinic visits in the previous 12 months; * Plan on receiving ongoing care at the clinic with the enrolled clinician for the subsequent 6 months; * Do not have vision or hearing problems that cannot be corrected; and * Have not recorded a clinic visit for personal use in the past 6 months Exclusion Criteria: * With no capacity to consent to the project; * With schizophrenia and other psychotic disorders, current substance-use disorders, uncorrected hearing or visual impairment with no adjustments to support accessing the interventions or surveys; * Living in skilled nursing homes or hospice, because they engage less in self-management; * With cognitive impairment as identified by a score of ≤4 on the six-item screener (SIS) * Lacking internet access; * Who do not speak English or Spanish; * Who (i) do not have access to a personal email, (ii) do not have an email address shared with a family member or patient-identified caregiver, and/or (iii) are not interested in creating a personal email as this would prevent them from engaging with the intervention(s); and * Who do not wish to create a patient portal account, if they do not already have one as this would prevent them from engaging with the intervention(s). CAREGIVERS: Inclusion criteria: * Agree to their identified role as a caregiver; * Speak English or Spanish; * Have capacity to consent to research participation; and * ≥ 18 years. Exclusion criteria: * No capacity to consent to the project; * Living in skilled nursing homes or hospice; * Lacking internet access; or * Do not speak English or Spanish

Inclusion Criteria: * Female aged \>= 18 years * Histologically confirmed advanced or metastatic TNBC that have relapsed on or are refractory to 2 or more lines of standard-of-care therapy. TNBC is defined as estrogen receptor (ER) and progesterone receptor negative (\< 10% immunohistochemistry \[IHC\] staining) and HER2 negative (IHC 1+ or 0 AND/OR in situ hybridization negative based on: * Single-probe average HER2 copy number \< 4.0 signals/cell * Dual-probe HER2/CEP17 ratio \< 2.0 with an average HER2 copy number \< 4.0 signals/cell) * HLA-A2+ and tumoral overexpression of NY-ESO-1 (2 to 3+ IHC staining in \> 50% of cells) * Have measurable disease based on RECIST 1.1 * Life expectancy \>= 6 months * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Hemoglobin \>= 9.0 g/dL (transfusions permitted) * Absolute neutrophil count (ANC) \>= 1500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Creatinine (Cr) \< 2 x upper limit of normal (ULN), and Cr clearance (CrCl) \>= 50 mL/min by Cockcroft and Gault * Alanine transaminase (ALT) and aspartate transaminase (AST) \< 2 x ULN (Patients with liver metastases whose ALT/AST are \< 5 x ULN are eligible for enrollment) * Bilirubin \< 2 x ULN * Lymphocyte count \>= 500/uL * Cardiac left ventricular ejection fraction (LVEF) \>= 50% * Negative serum pregnancy (human chorionic gonadotropin \[beta-hCG\]) test within 7 days of leukapheresis for women of childbearing potential (WOCBP). WOCBP must be willing to use a highly effective method of contraception for the course of the study through 90 days after A2-ESO-1 TCR-engineered T cell infusion * Willing and able to provide written informed consent for the study * Willing to provide biopsy tissues and blood samples as required by the study Exclusion Criteria: * Radiation therapy, chemotherapy, or non-cytotoxic investigational agent within 2 weeks of leukapheresis * Received cyclophosphamide within the past 4 months * Evidence of New York Heart Association class III or greater cardiac disease * History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within the past 12 months * History of congenital QT prolongation * Absolute QT interval of \> 470 msec in the presence of \> 4.0 mEq/L potassium and \> 1.8 mg/dL magnesium * Brain or leptomeningeal metastases * Females who are pregnant or breastfeeding * Hypersensitivity or intolerance to cyclophosphamide, fludarabine, IL-2, or their components * History of clinically significant gastrointestinal bleeding, gastric or intestinal ulceration, or perforation within 6 months of enrollment. * Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study, such as severely impaired lung function, any active (acute or chronic) or uncontrolled infection/disorders, and non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the study treatment * Current use of medications that interact with or compromise the immune system such as steroid doses \> 10 mg/day prednisone or equivalent daily within 2 weeks before leukapheresis * History of immunodeficiency disease or autoimmune disease, with exceptions such as Hashimoto's thyroiditis / hypothyroidism, or controlled Type 1 diabetes * Have any active and uncontrolled infection. * Active hepatitis B (as defined as positive hepBsAntigen or detectable hepatitis B DNA) or hepatitis C infection. Patients who are hepatitis B surface Antigen negative and have a negative hep B DNA are allowed. If hepatitis C antibody test is positive, then patients must be tested for the presence of antigen by RT-PCR and be HCV RNA negative. Patients with laboratory evidence of cleared hepatitis B or C infection may enroll. Patients with no prior history of hepatitis B infection who have been vaccinated against hepatitis B and who have a positive antibody against hepatitis B surface antigen as the only evidence of prior exposure may enroll. Patients with a history of hepatitis C infection may be eligible if they have completed antiviral treatment and show no detectable HCV RNA for 6 months prior to enrollment. * Human immunodeficiency virus (HIV) infection or seropositive for HIV antigens * Concurrent use of any complementary or alternative medicines * Unwilling or unable to comply with the study protocol * Prior major surgery that requires general anesthesia must be completed at least 4 weeks before leukapheresis and surgery that requires local anesthesia (except for study tissue sample collection) must be completed at least 2 weeks before leukapheresis and surgery that requires local anesthesia (except for study tissue sample collection) must be completed at least 2 weeks before leukapheresis